Report overview
Mucopolysaccharidosis consists of a group of more than 40 genetic disorders that forms a part of lysosomal storage disease. They are caused by an inherited deficiency of an enzyme involved in the degradation of acid glycosaminoglycans (GAGs), which was previously known as mucopolysaccharidosis. All of the mucopolysaccharidoses are rare, autosomal recessive, except for mucopolysaccharidosis III, as it is X-linked.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Mucopolysaccharidosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Mucopolysaccharidosis. This report contains market size and forecasts of Gene Therapy for Mucopolysaccharidosis in global, including the following market information:
Global Gene Therapy for Mucopolysaccharidosis Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Gene Therapy for Mucopolysaccharidosis market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Over the past few years, gene therapy has emerged as one of the most exciting approaches for the treatment of mucopolysaccharidosis. One of the promising therapy is replacement gene therapy, which replaces faulty genes with normal ones in the body. It is considered to be a potential cure to mucopolysaccharidoses and a promising option in the long run.
We surveyed the Gene Therapy for Mucopolysaccharidosis companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene Therapy for Mucopolysaccharidosis Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Mucopolysaccharidosis Market Segment Percentages, by Type, 2022 (%)
Intravenous
ICV
Intracerebral
Intracisternal
Global Gene Therapy for Mucopolysaccharidosis Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Mucopolysaccharidosis Market Segment Percentages, by Application, 2022 (%)
Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis III A
Mucopolysaccharidosis III B
Global Gene Therapy for Mucopolysaccharidosis Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Gene Therapy for Mucopolysaccharidosis Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gene Therapy for Mucopolysaccharidosis revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Gene Therapy for Mucopolysaccharidosis revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sangamo Therapeutics
Swedish Orphan Biovitrum
uniQure
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene Therapy for Mucopolysaccharidosis, market overview.
Chapter 2: Global Gene Therapy for Mucopolysaccharidosis market size in revenue.
Chapter 3: Detailed analysis of Gene Therapy for Mucopolysaccharidosis company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene Therapy for Mucopolysaccharidosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
